Results 51 to 60 of about 11,634 (196)
Platelets, 2020 Knowledge of platelet count and function is key to ensuring appropriate hemostatic management. We hypothesized that the novel, portable TEG®6s coagulation assessment system could evaluate the contribution of both platelet count and function to clot ...
Joao D. Dias +5 more
doaj +1 more source
Newer agents in antiplatelet therapy: a review. [PDF]
, 2012 Antiplatelet therapy remains the mainstay in preventing aberrant platelet activation in pathophysiological conditions such as myocardial infarction, ischemia, and stroke.
Holinstat, Michael, Yeung, Jennifer
core +3 more sources
Catheterization and Cardiovascular Interventions, Volume 106, Issue 3, Page 2037-2047, September 1, 2025.ABSTRACT The patent foramen ovale (PFO), present in 25% of the population, can cause paradoxical embolism and stroke. Transcatheter PFO closure is the gold standard for recurrent embolism with significant inter‐atrial shunting, with recent trials confirming its superiority in reducing ischemic stroke recurrence over medical therapy.
Eirini Beneki +13 more
wiley +1 more source
Self-Reporting Theranostic: Nano Tool for Arterial Thrombosis
Bioengineering, 2023 Arterial thrombosis (AT) originates through platelet-mediated thrombus formation in the blood vessel and can lead to heart attack, stroke, and peripheral vascular diseases.
Suryyani Deb +6 more
doaj +1 more source
Myeloperoxidase Serum Levels Predict Risk in Patients With Acute Coronary Syndromes [PDF]
, 2003 BACKGROUND: Polymorphonuclear neutrophils (PMNs) have gained attention as critical mediators of acute coronary syndromes (ACS). Myeloperoxidase (MPO), a hemoprotein abundantly expressed by PMNs and secreted during activation, possesses potent ...
Eiserich, J.P. (Jason) +6 more
core +1 more source
Adjuvant antithrombotic therapy in ST-elevation myocardial infarction: A narrative review
Revista Portuguesa de Cardiologia, 2019 This article reviews the major pharmacologic features of, and clinical evidence on, adjuvant medical therapy in patients with ST-elevation myocardial infarction (STEMI) treated with primary percutaneous coronary intervention.
Daniel Caldeira, Hélder Pereira
doaj +1 more source
Administration of a Glycoprotein IIb/IIIa Receptor Blocker with a Thienopyridine Derivative Does Not Increase the Risk of Thrombocytopenia [PDF]
, 2005 Author Institution: Akron Cardiology Consulltants, OHAuthor Institution: Dept. of Educational Foundations & Leadership, University of Akron, OHAuthor Institution: Summa Health System, University of Akron, OHAuthor Institution: Dept.
Johnson, Jeremy +4 more
core
The FRED‐X Flow Diverter—An Australian Experience
Journal of Medical Imaging and Radiation Oncology, Volume 69, Issue 4, Page 484-490, June 2025.ABSTRACT Background The FRED X flow diverter features antithrombotic surface treatment to reduce thrombogenicity. This study evaluated the safety and efficacy of FRED X in treating intracranial aneurysms in the Australian setting. Methods Clinical, procedural and imaging data were retrospectively reviewed for a consecutive series of patients at a ...
Peter Shuangyue Tan +6 more
wiley +1 more source
Statistical analysis of the primary outcome in acute stroke trials [PDF]
, 2012 Common outcome scales in acute stroke trials are ordered categorical or pseudocontinuous in structure but most have been analyzed as binary measures. The use of fixed dichotomous analysis of ordered categorical outcomes after stroke (such as the modified
Altman, H. +7 more
core +1 more source
Journal of Small Animal Practice, Volume 66, Issue 6, Page 365-371, June 2025.Objectives Thromboelastography (TEG) using the TEG 6s, a point‐of‐care viscoelastic assay, was prospectively evaluated in dogs with chronic enteropathy (CE). Additionally, the study determined whether disease activity, assessed using the Canine Chronic Enteropathy Clinical Activity Index (CCECAI), correlated with TEG 6s parameters.
S. I. Barth +3 more
wiley +1 more source